CHARACTERIZATION IN VIVO OF TWO DIFFERENT MOLECULAR MECHANISMS INVOLVED IN THE DEVELOPMENT OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY

Cristina Meregalli¹, Federica La Russa¹, Alessia Chiorazzi¹, Barbara Sala¹, Annalisa Canta¹, Guido Cavaletti¹

¹Department of Neuroscience and Biomedical Technologies, University of Milan-Bicocca, Monza, Italy.

Bortezomib (BTZ) is a chemotherapy drug with clinical efficacy in patients with relapsed/refractory, relapsed and newly diagnosed multiple myeloma (MM). It acts by inhibiting protein degradation by the proteasome, but its clinical use is limited by a dose-limiting neurotoxicity and by the development of tumor resistance. BTZ-induced peripheral neuropathy may occur in cancer patients from a variety of mechanisms, among which proteasome inhibition and the alteration of microtubule’s stability. To study in vivo these two different mechanisms involved in the onset of neuropathy, we used a well-characterized rat model of BTZ-induced peripheral neuropathy. Wistar rat were administered with BTZ 0.20 mg/kg, three times/week for eight weeks. At the end of the treatment period the relationship between neurotoxicity and the profile of the proteasome inhibition was evaluated in different tissues. The level of 20S proteasome inhibition was assessed by the proteasome activity assay into blood mononuclear cells (PBMC), sciatic nerve and brain by fluorimetric assay at different time points. Moreover, we examined microtubule polymerization in sciatic nerve by comparing the distribution of acetylated tubulin (a post translational marker of stabilized microtubule) between polymerized (P) and soluble (S) fractions by western blot experiments.

After eight weeks of treatment, we observed BTZ-related neurophysiologic alterations and neuropathological damages in the axons of sciatic nerves and in sensory neurons and satellite cells of dorsal root ganglia, demonstrating the onset of a peripheral neuropathy. The recovery of the proteasome activity was observed within 24 hours from the drug administration if BTZ was injected in a single acute dose; while the proteasome activity remained suppressed if the drug was chronically administered. This effect was probably due to a cumulative effect of chronic administration of BTZ on its biological target. Besides, in this study we increase in the amount of acetylated-tubulin in the polymerized fraction in BTZ-treated sciatic nerves as compared with control animals. This preclinical work provide a potential explanation for the development of BTZ-induced peripheral neuropathy, through the bortezomib’s ability to induce a chronic proteasome inhibition and to suppress the cytoskeleton dynamics.

In conclusion, this model showed a toxic effect on peripheral nervous system induced by a prolonged BTZ-induced of proteasome inhibition and stabilized microtubule. Therefore this model can be useful for the study of “de novo” proteasome synthesis that can be useful for the recovery of its activity. Moreover this work will enable us to better characterize the potential role of microtubule stabilization in the neurotoxicity of bortezomib.

Supported in part by grants from the “Fondazione Banca del Monte di Lombardia”